Sirolimus - Angiofibroma from tuberous sclerosis complex
You are here : Home > Formulary Search > Sirolimus - Angiofibroma from tuberous sclerosis complex
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Status 1
See narrative
Formulations :
- Gel
Formulary Status :
Associated Icons :
NFD2
SPC
Restrictions / Comments :
Important
This drug has not been assessed for formulary status.
NICE is unable to make a recommendation because the company has not provided an evidence submission. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their formulary team to discuss possible alternatives/options
Documentation
PAD Profile
ChemicalSubstance :
Sirolimus
Indication :
Angiofibroma from tuberous sclerosis complex
Group Name :
Keywords :
Face
Brand Names Include :
Hyftor
Important Information :
Latest Additions Date From :
04 Feb 2026
Latest Additions Date To :
04 Mar 2026
Guidelines :
Supporting Documents :
1
Committee Recommendations (0)
- No records returned.
Other Indications
Below are listed other indications that Sirolimus is used to treat.
Other Drugs
Below are listed other drugs that are used to treat Angiofibroma from tuberous sclerosis complex.
- No records returned.